Elena Caproni

TL;DR: In vivo potency can be increased with little to no systemic exposure, localized innate immune activation and short in vivo residence times of SMIP-based adjuvants, and this work provides a systematic and generalizable approach to engineering small molecules for use as vaccine adjuvant.

TL;DR: Insight into the functioning of the innate immune system has demonstrated its important role in triggering and shaping the adaptive immune response to vaccines, and many adjuvants have been tested in humans and are in advanced stages of development.

TL;DR: It is found that flu adjuvanticity correlates with the upregulation of proinflammatory genes and other genes involved in leukocyte transendothelial migration at the vaccine injection site and by blocking IFN type I receptor through a mAb, it is confirmed that the adjUvanticity of MF59 and Pam3CSK4 to a trivalent influenza vaccine and to TT is IFN independent.

TL;DR: This study paves the way for the development of an effective anti-Chlamydia vaccine and provides a general approach for the discovery of vaccines against other intracellular pathogens.

TL;DR: Results show that variation of host Hsp90 expression or activity interferes with adhesive and invasive events driven by NadA, and suggest an inverse correlation between the amount of hostHsp90 and the NadA adhesive/invasive phenotype.